Abstract
This study evaluates metal ion levels in patients enrolled in a prospective evaluation of hip resurfacing arthroplasty utilizing the Conserve Plus implant (Wright Medical Technology). Serum, urine and erythrocyte metal ion levels were assessed preoperatively and postoperatively. Average levels at three months were 24 nmol/l for cobalt and 40 nmol/l for chromium. These increased to 40 nmol/l for cobalt and 80 nmol/l for chromium at the six-month mark. The clinical significance of increased metal ion levels is yet to be determined.
To evaluate the clinical, functional and radiographic outcome of hip resurfacing arthroplasty utilizing the Conserve Plus implant (Wright Medical Technology). Serum, urine and erythrocyte metal ion levels were evaluated both pre and postoperatively.
Ion levels for both cobalt and chromium increased from the three-month to the six-month mark postoperatively and were significantly elevated relative to preoperative values.
This study helps to establish a baseline for metal ion levels following hip resurfacing arthroplasty.
Serum, urine and erythrocyte metal ion levels were assessed preoperatively and postoperatively. All levels were within normal range preoperatively. Average serum levels at three months were 24 nmol/l for cobalt and 40 nmol/l for chromium. These increased to 40 nmol/l for cobalt and 80 nmol/l for chromium at the six-month mark. Average erythrocyte metal ion levels at three months were 0.92 ug/l for cobalt and 1.8 ug/l for chromium. The average erythrocyte levels at six months were 1.3 ug/l for cobalt and 2.0 ug/l for chromium.
A prospective multi-center study to evaluate the outcome of hip resurfacing arthroplasty was initiated in July 2003. Each patient was evaluated preoperatively and postoperatively with outcome scores, radiographs as well as serum, urine and erythrocyte metal ion levels.
The results of this prospective evaluation show a rise in ion levels from three to six months postoperatively. Further follow-up is necessary to assess future trends with respect to the ion levels as well as the clinical significance.
Funding: This study has been sponsored in part by Wright Medical Technology.
Correspondence should be addressed to Cynthia Vezina, Communications Manager, COA, 4150-360 Ste. Catherine St. West, Westmount, QC H3Z 2Y5, Canada
